NYSEAMERICAN:PLX - Protalix BioTherapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 343.04 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.07 (4.64%)

This chart shows the closing price for PLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Protalix BioTherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PLX

Analyst Price Target is $7.00
▲ +343.04% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Protalix BioTherapeutics in the last 3 months. The average price target is $7.00, with a high forecast of $7.00 and a low forecast of $7.00. The average price target represents a 343.04% upside from the last price of $1.58.

This chart shows the closing price for PLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Protalix BioTherapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/3/2021HC WainwrightLower Price TargetBuy$11.00 ➝ $7.00
6/8/2020HC WainwrightBoost Price TargetBuy$3.00 ➝ $11.00
10/18/2019HC WainwrightSet Price TargetBuy$30.00
10/2/2019HC WainwrightReiterated RatingBuy$30.00
6/10/2019HC WainwrightReiterated RatingBuy$30.00
3/19/2019HC WainwrightSet Price TargetBuy$30.00
12/13/2018HC WainwrightSet Price TargetBuy$40.00
10/9/2018HC WainwrightSet Price TargetBuy$40.00
9/24/2018HC WainwrightReiterated RatingBuy$40.00
8/13/2018HC WainwrightSet Price TargetBuy$40.00
7/25/2018HC WainwrightSet Price TargetBuy$40.00
6/11/2018HC WainwrightSet Price TargetBuy$50.00
5/11/2018HC WainwrightSet Price TargetBuy$50.00
3/14/2018HC WainwrightSet Price TargetBuy$50.00
3/7/2018HC WainwrightSet Price TargetBuy$50.00
2/12/2018HC WainwrightSet Price TargetBuy$50.00
2/1/2018HC WainwrightReiterated RatingBuy$50.00
1/4/2018HC WainwrightSet Price TargetBuy$50.00
11/29/2017HC WainwrightSet Price TargetBuy$50.00
11/9/2017HC WainwrightReiterated RatingBuy$50.00
8/10/2017HC WainwrightSet Price TargetBuy$50.00
5/23/2017Rodman & RenshawReiterated RatingBuy$50.00
4/17/2017Rodman & RenshawBoost Price TargetBuy$40.00 ➝ $50.00
4/17/2017Rodman & RenshawReiterated RatingBuy ➝ Buy$40.00 ➝ $50.00
12/15/2016MackieReiterated RatingBuy$10.00
12/13/2016MackieInitiated CoverageBuy$10.00
12/13/2016MackieSet Price TargetBuyC$10.00
9/6/2016Jefferies Financial GroupLower Price TargetBuy$17.50 ➝ $8.00
(Data available from 8/2/2016 forward)
Protalix BioTherapeutics logo
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.
Read More

Today's Range

Now: $1.58
Low: $1.53
High: $1.58

50 Day Range

MA: $3.55
Low: $3.15
High: $3.98

52 Week Range

Now: $1.58
Low: $1.46
High: $7.02


629,553 shs

Average Volume

1,472,714 shs

Market Capitalization

$71.71 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Protalix BioTherapeutics?

The following sell-side analysts have issued reports on Protalix BioTherapeutics in the last year: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for PLX.

What is the current price target for Protalix BioTherapeutics?

1 Wall Street analysts have set twelve-month price targets for Protalix BioTherapeutics in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 343.0%. HC Wainwright has the highest price target set, predicting PLX will reach $7.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $7.00 for Protalix BioTherapeutics in the next year.
View the latest price targets for PLX.

What is the current consensus analyst rating for Protalix BioTherapeutics?

Protalix BioTherapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PLX will outperform the market and that investors should add to their positions of Protalix BioTherapeutics.
View the latest ratings for PLX.

What other companies compete with Protalix BioTherapeutics?

How do I contact Protalix BioTherapeutics' investor relations team?

Protalix BioTherapeutics' physical mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company's listed phone number is +972-4-9028100 and its investor relations email address is [email protected] The official website for Protalix BioTherapeutics is www.protalix.com.